More trouble for embattled EpiPen maker Mylan (MYL) . Two U.S. senators claim Mylan overcharged Medicaid for some twenty years to the tune of millions of dollars. The lawmakers say the EpiPen was misclassified as a generic drug. That means Mylan was paying lower rebates to Medicaid, than if the drug was under the brand name category. Mylan came under intense scrutiny for raising the price of the life saving drug. TheStreet's Scott Gamm reports from Wall Street.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.